Forian Inc. Announces Second Quarter 2024 Financial Results

Forian Inc.

(Nasdaq: FORA)

, a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter ended June 30, 2024.

“We continued to invest in our information assets in the second quarter to further differentiate our offerings and the insights they power for our customers. We remain confident that our combination of thoughtful productization, diversification of data sources and prudent cost containment put us in solid position to manage through recent industry challenges and to continue our contribution to our customers’ success,” stated Max Wygod, Chairman and Chief Executive Officer of Forian.

Second Quarter 2024 Financial Results

• Forian delivered the following results for the second quarter of 2024:

			Three Months EndedJune 30,								Period-over-Period % Change
			2024Unaudited				2023Unaudited
Revenue			$	4,777,101			$	4,893,542			-2	%
Loss from continuing operations, net of tax			$	(2,553,259	)		$	(1,090,400	)		-134	%
(Loss) income from discontinued operations, net of tax			$	-			$	(32,426	)		-100	%
Net (loss) income			$	(2,553,259	)		$	(1,122,826	)		-127	%
Loss from continuing operations, net of tax per share – basic and diluted			$	(0.08	)		$	(0.03	)		-167	%
Income from discontinued operations, net of tax per share – basic and diluted			$	-			$	-			0	%
(Loss) Income per share – basic and diluted			$	(0.08	)		$	(0.03	)		-167	%
Adjusted EBITDA (a non-GAAP financial measure defined below)			$	78,202			$	417,368			-81	%

• Revenue for the quarter was $4.8 million, a $0.1 million decrease from $4.9 million in the prior year
• Net loss from continuing operations for the quarter was $2.6 million, or $0.08 per share, compared to a net loss of $1.1 million, or $0.03 per share, in the prior year
• Adjusted EBITDA for the quarter was $0.08 million, compared to $0.4 million in the prior year
• Cash, cash equivalents and marketable securities at June 30, 2024 totaled $48.0 million

Highlights

• Continued expansion of Chronos™ data lake through license of additional data to offset the reduction and expected 2025 loss of certain data from one data supplier
• Maintained positive Adjusted EBITDA despite revenue impact resulting from financing challenges of two early-stage customers

Full Year 2024 Outlook

Based on information as of August 14, 2024, the Company is updating its outlook for the year ending December 31, 2024 as follows:

• Revenue is expected to be in the range of $19 to $20 million
• Adjusted EBITDA is expected to be in the range of negative $0.5 million to $0.5 million

This release uses non-GAAP financial measures that are adjusted for the impact of various U.S. GAAP items. See the section titled “Non-GAAP Financial Measures” and the table entitled “Reconciliation of U.S. GAAP to Non-GAAP Financial Measures” below for details.

Quarterly Conference Call and Webcast

Forian will host a conference call and webcast at 4:30 p.m. ET on August 14, 2024 to discuss its financial results with the investment community. To register for the conference call, click here. The webcast will be available live at https://edge.media-server.com/mmc/p/c5ot6k5y. This information is also available on our website at www.forian.com/investors. To be included on the Company’s email distribution list, please sign up at www.forian.com/investors.

About ForianForian provides a unique suite of data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical and financial performance for customers within the traditional and emerging life sciences and healthcare payer and provider segments. Forian has industry leading expertise in acquiring, integrating, normalizing and commercializing large scale healthcare data assets. Forian’s information products overlay sophisticated data management and data science capabilities on top of a comprehensive clinical data lake to identify unique relationships, create distinctive information assets and generate proprietary insights. For more information, please visit the Company’s website at www.forian.com.

Cautionary Statements Regarding Forward-Looking StatementsThis release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, which may include GAAP and non-GAAP financial measures, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions and variations or negatives of these words. Forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond our control and are not guarantees of future results, such as statements about future financial and operating results, company strategy and intended product offerings and market positioning. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements. Our updated 2024 outlook contained in this release is based on current estimates as of today’s date that are subject to such factors. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with operations, strategy and goals, our ability to execute on our strategy and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in Forian’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on March 29, 2024, and elsewhere in Forian’s filings and reports with the SEC. Forward-looking statements contained in this release are made as of the date hereof, and we undertake no duty to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

Media and Investor Contact:forian.com/[e-mail]267-225-6263SOURCE: Forian Inc.

FORIAN INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
	June 30,				December 31,
		2024				2023
	(UNAUDITED)
ASSETS
Current assets:
Cash and cash equivalents	$	1,999,118			$	6,042,986
Marketable securities		46,011,230				42,296,589
Accounts receivable, net		3,670,368				2,572,931
Proceeds receivable from sale of discontinued operation, net		-				1,645,954
Contract assets		955,355				1,126,713
Prepaid expenses		1,015,985				1,077,233
Other assets		2,783,185				2,515,509
Total current assets		56,435,241				57,277,915
Property and equipment, net		59,309				76,085
Right of use assets, net		46,876				10,664
Deposits and other assets		1,828,425				1,523,948
Total assets	$	58,369,851			$	58,888,612
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	1,489,766			$	161,590
Accrued expenses		3,320,571				4,252,257
Short-term operating lease liabilities		22,872				10,664
Warrant liability		20				563
Deferred revenues		3,202,703				2,413,551
Total current liabilities		8,035,932				6,838,625
Long-term liabilities:
Other liabilities		524,004				1,000,000
Convertible notes payable, net of debt issuance costs ($6,000,000 in principal is held by a related party)		24,175,094				24,870,181
Total long-term liabilities		24,699,098				25,870,181
Total liabilities		32,735,030				32,708,806
Commitments and contingencies
Stockholders' equity:
Preferred Stock; par value $0.001; 5,000,000 Shares authorized; 0 issued and outstanding as of June 30, 2024 and December 31, 2023		-				-
Common Stock; par value $0.001; 95,000,000 Shares authorized; 31,110,187 issued and outstanding as of March 31, 2024 and 30,920,450 issued and outstanding as of December 31, 2023		31,110				30,920
Additional paid-in capital		77,054,999				73,834,300
Accumulated deficit		(51,451,288	)			(47,685,414	)
Total stockholders' equity		25,634,821				26,179,806
Total liabilities and stockholders' equity	$	58,369,851			$	58,888,612

FORIAN INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
	For the Three Months Ended June 30,								For the Six Months Ended June 30,
		2024				2023				2024				2023
Revenue	$	4,777,101			$	4,893,542			$	9,654,479			$	9,763,929
Costs and Expenses:
Cost of revenue		1,806,918				1,276,712				3,510,275				2,528,927
Research and development		307,201				304,187				697,090				835,876
Sales and marketing		1,017,659				1,237,327				2,072,800				2,433,519
General and administrative		3,665,601				3,198,290				6,949,090				6,753,765
Separation expenses		-				-				-				599,832
Depreciation and amortization		7,889				15,257				16,776				53,687
Litigation settlements and related expenses		942,311				350,309				1,151,276				434,660
Total costs and expenses		7,747,579				6,382,082				14,397,307				13,640,266
Operating loss From Continuing Operations		(2,970,478	)			(1,488,540	)			(4,742,828	)			(3,876,337	)
Other Income (Expense):
Change in fair value of warrant liability		430				8,053				543				2,494
Interest and investment income		618,316				637,032				1,293,473				1,019,954
Gain on sale of investment		-				-				48,612				-
Interest expense		(193,306	)			(210,758	)			(392,269	)			(419,214	)
Gain on debt redemption		-				-				137,356				-
Total other income (expense), net		425,440				434,327				1,087,715				603,234
Loss from continuing operations before income taxes		(2,545,038	)			(1,054,213	)			(3,655,113	)			(3,273,103	)
Income taxes		(8,221	)			(36,187	)			(110,761	)			(66,096	)
Loss from continuing operations, net of tax		(2,553,259	)			(1,090,400	)			(3,765,874	)			(3,339,199	)
Loss from discontinued operations		-				-				-				(94,427	)
Gain on sale of discontinued operations		-				-				-				11,531,849
Income tax effect on discontinued operations		-				(32,426	)			-				(2,722,570	)
Income from discontinued operations, net of tax		-				(32,426	)			-				8,714,852
Net (loss) income	$	(2,553,259	)		$	(1,122,826	)		$	(3,765,874	)		$	5,375,653
Net (loss) income per share
Basic and diluted
Continuing operations	$	(0.08	)		$	(0.03	)		$	(0.12	)		$	(0.10	)
Discontinued operations	$	-			$	-			$	-			$	0.27
Net (loss) income per share - basic and diluted	$	(0.08	)		$	(0.03	)		$	(0.12	)		$	0.17
Weighted-average shares outstanding		31,098,497				32,260,992				31,049,647				32,369,904

FORIAN INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
		For the Period Ended June 30,
			2024				2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income		$	(3,765,874	)		$	5,375,653
Less: Income from discontinued operations			-				8,714,852
Loss from continuing operations			(3,765,874	)			(3,339,199	)
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities - continuing operations:
Depreciation and amortization			16,776				53,687
Amortization on right of use asset			10,664				11,724
Amortization of debt issuance costs			2,667				2,667
Accrued interest on convertible Notes			389,602				416,548
Amortization of discount - proceeds from sale of discontinued operations			(20,712	)			(245,041	)
Accretion of discount - marketable securities			(1,237,337	)			(767,533	)						`
Gain on sale of investment			(48,612	)			-
Gain on debt redemption			(137,356	)			-
Provision for doubtful accounts			168,750				-
Stock-based compensation expense			3,321,551				3,368,575
Change in fair value of warrant liability			(543	)			(2,494	)
Change in operating assets and liabilities:
Accounts receivable			(1,266,187	)			(2,030,800	)
Contract assets			171,358				442,616
Prepaid expenses			61,248				(132,344	)
Changes in lease liabilities during the period			(21,624	)			(11,724	)
Deposits and other assets			(572,153	)			(235,656	)
Accounts payable			1,328,176				605,437
Accrued expenses			(931,686	)			(236,088	)
Deferred revenues			789,152				681,476
Other liabilities			(489,040	)			-
Net cash used in operating activities - continuing operations			(2,231,180	)			(1,418,149	)
Net cash used in operating activities - discontinued operations			-				(59,075	)
Net cash used in operating activities			(2,231,180	)			(1,477,224	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment			-				(75,493	)
Purchase of marketable securities			(87,732,380	)			(61,573,237	)
Sale of marketable securities			85,255,076				41,392,821
Proceeds from sale of investment			48,612				-
Cash from sale of discontinued operations			1,666,666				21,967,193
Net cash (used in) provided by investing activities - continuing operations			(762,026	)			1,711,284
Net cash (used in) provided by investing activities			(762,026	)			1,711,284
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash used to redeem convertible notes			(950,000	)			-
Tax payments related to shares withheld for vested restricted stock units			(100,662	)			(127,357	)
Net cash used in financing activities- continuing operations			(1,050,662	)			(127,357	)
Net cash used in financing activities			(1,050,662	)			(127,357	)
Net change in cash			(4,043,868	)			106,703
Cash and cash equivalents, beginning of period			6,042,986				2,795,743
Cash and cash equivalents, end of period		$	1,999,118			$	2,902,446
Supplemental disclosure of cash flow information:
Cash for paid for taxes		$	48,492			$	1,423,000

Non-GAAP Financial Measures

In this press release, we have provided certain non-GAAP measures, which we define as financial information that has not been prepared in accordance with U.S. GAAP. The non-GAAP financial measure provided herein is earnings before interest, taxes, non-cash and other items (“Adjusted EBITDA”), which should be viewed as supplemental to, and not as an alternative for, net income or loss calculated in accordance with U.S. GAAP (referred to below as “net loss”).

Adjusted EBITDA is used by our management as an additional measure of our Company’s performance for purposes of business decision-making, including developing budgets, managing expenditures and evaluating potential acquisitions or divestitures. Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our Company’s financial results that may not be shown solely by period-to-period comparisons of net income. In addition, we may use Adjusted EBITDA in the incentive compensation programs applicable to some of our employees in order to evaluate our Company’s performance. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, particularly those items that are recurring in nature. In order to compensate for those limitations, management also reviews the specific items that are excluded from Adjusted EBITDA, but included in net income, as well as trends in those items.

We believe that the presentation of Adjusted EBITDA is useful to investors in their analysis of our results for reasons similar to the reasons why our management finds it useful and because it helps facilitate investor understanding of decisions made by management in light of the performance metrics used in making those decisions. In addition, as more fully described below, we believe that providing Adjusted EBITDA, together with a reconciliation of net loss to Adjusted EBITDA, helps investors make comparisons between our Company and other companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation. However, Adjusted EBITDA is not intended as a substitute for comparisons based on net loss. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding U.S. GAAP measures provided by each company under applicable SEC rules.

The following is an explanation of the items excluded by us from Adjusted EBITDA but included in net loss:

• Depreciation and Amortization. Depreciation and amortization expense is a non-cash expense relating to capital expenditures and intangible assets arising from acquisitions that are expensed on a straight-line basis over the estimated useful life of the related assets. The Company excludes depreciation and amortization expense from Adjusted EBITDA because management believes that (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of the business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired tangible and intangible assets. Accordingly, management believes that this exclusion assists management and investors in making period-to-period comparisons of operating performance. Investors should note that the use of tangible and intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation and should also note that such expense will recur in future periods.
• Stock-Based Compensation Expense. Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards to employees. Management believes that excluding the effect of stock-based compensation from Adjusted EBITDA assists management and investors in making period-to-period comparisons in the Company’s operating performance because (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of business operations and (ii) such expenses can vary significantly between periods as a result of the timing of grants of new stock-based awards, including grants in connection with acquisitions. Stock-based compensation expense includes certain separation expenses related to the vesting of stock options. Effective February 10, 2023, the Company’s Chief Executive Officer, President and Class II member of the Board of Directors resigned. In connection with the resignation, the Company entered into a separation agreement providing for, among other things, accelerated vesting of 106,656 unvested restricted shares of the Company common stock. Stock based compensation expense for 2023 includes $349,832 related to the accelerated vesting of stock, which is recognized in separation expenses in the condensed consolidated statements of operations. These expenses were incurred during the three months ended March 31, 2023, and there were no additional related expenses incurred during the three months ended June 30, 2023. Management believes that excluding stock-based compensation from Adjusted EBITDA assists management and investors in making meaningful comparisons between the Company’s operating performance and the operating performance of other companies that may use different forms of employee compensation or different valuation methodologies for their stock-based compensation. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods. Investors should also note that such expenses will recur in the future.
• Interest Expense. Interest expense is associated with the convertible notes entered into on September 1, 2021 in the amount of $24,000,000. The Notes are due on September 1, 2025, and accrue interest at an annual rate of 3.5%. Management excludes interest expense from Adjusted EBITDA (i) because it is not directly attributable to the performance of business operations and, accordingly, its exclusion assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different capital structures. Investors should note that interest expense associated with the Notes will recur in future periods.
• Investment Income. Investment income is associated with the level of marketable debt securities and other interest-bearing accounts in which the Company invests. Interest and investment income can vary over time due to changes in interest rates and level of investments. Management excludes interest and investment income from Adjusted EBITDA (i) because these items are not directly attributable to the performance of business operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different capital structures. Investors should note that interest income will recur in future periods.
• Other Items. The Company engages in other activities and transactions that can impact net income (loss). In the periods reported, these other items included (i) change in fair value of warrant liability relating to warrants assumed in the acquisition of Helix; (ii) gain on sale of investment relating to the sale of a minority equity interest; and (iii) gain on debt redemption which relates to a gain on the early retirement of a portion of the convertible notes. Management excludes these other items from Adjusted EBITDA because management believes these activities or transactions are not directly attributable to the performance of business operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating performance. Investors should note that some of these other items may recur in future periods.
• Severance expenses. Effective February 10, 2023, the Company’s Chief Executive Officer, President and Class II member of the Board of Directors resigned. In connection with the resignation, the Company entered into a separation agreement providing for, among other things, (i) salary continuation for twelve months and (ii) accelerated vesting of 106,656 unvested restricted shares of the Company common stock. Severance expenses for the six months ended June 30, 2023 includes $250,000 related to the salary continuation. Managements excludes these other items from Adjusted EBITDA because management believes these costs are not recurring and not directly attributable to the performance of business operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating performance. In addition, the Company records normal course of business severance expenses in the operating expense line item related to its employees’ activities.
• Litigation related expenses. Management excludes litigation expenses that are extraordinary in nature and are unrelated to the Company’s day-to-day business operations. The nature of these expenses is primarily related to direct and incremental third-party legal expenses associated with such litigation, which pertains to entities acquired in the Helix merger.
• Strategic review related expenses. Management excludes certain professional expenses that are extraordinary in nature and are unrelated to the Company’s day-to-day business operations. The nature of these expenses is primarily related to a strategic review of the Company’s operations.
• Income tax expense. Management excludes the income tax expense from Adjusted EBITDA (i) because management believes that the income tax expense is not directly attributable to the underlying performance of business operations and, accordingly, its exclusion assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different tax attributes.

There are limitations to using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with U.S. GAAP and may be different from non-GAAP financial measures provided by other companies.

The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon our reported financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which items are adjusted to calculate our non-GAAP financial measures. We compensate for these limitations by analyzing current and future results on a U.S. GAAP basis as well as a non-GAAP basis and also by providing U.S. GAAP measures in our public disclosures.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with U.S. GAAP. We encourage investors and others to review our financial information in its entirety, not to rely on any single financial measure to evaluate our business and to view our non-GAAP financial measures in conjunction with the most directly comparable U.S. GAAP financial measures.

The following table reconciles the specific items excluded from U.S. GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

FORIAN INC.
RECONCILIATION OF US GAAP TO NON-GAAP FINANCIAL MEASURES
(UNAUDITED)
	For the Three Months Ended June 30,								For the Six Months Ended June 30,
		2024				2023				2024				2023
Revenue	$	4,777,101			$	4,893,542			$	9,654,479			$	9,763,929
Net loss from continuing operations	$	(2,553,259	)		$	(1,090,400	)		$	(3,765,874	)		$	(3,339,199	)
Depreciation and amortization		7,889				15,257				16,776				53,687
Stock based compensation expense		1,662,636				1,540,342				3,321,551				3,368,575
Change in fair value of warrant liability		(430	)			(8,053	)			(543	)			(2,494	)
Interest and investment income		(618,316	)			(637,032	)			(1,293,473	)			(1,019,954	)
Interest expense		193,306				210,758				392,269				419,214
Gain on sale of investment		-				-				(48,612	)			-
Gain on debt redemption		-				-				(137,356	)			-
Severance expense		-				-				-				250,000
Litigation settlement and related expenses		942,311				350,309				1,151,276				434,660
Strategic review related expenses		435,844								435,844
Income tax expense		8,221				36,187				110,761				66,096
Adjusted EBITDA - continuing operations	$	78,202			$	417,368			$	182,619			$	230,585